Comparison of gene therapy with the herpes simplex virus thymidine kinase gene and the bacterial cytosine deaminase gene for the treatment of hepatocellular carcinoma

Scand J Gastroenterol. 1999 Oct;34(10):1033-41. doi: 10.1080/003655299750025156.

Abstract

Background: Bystander effects induced by suicide gene/prodrug systems play an essential role in achieving successful antitumor effects. Although it has been shown in several in vitro studies that the bacterial cytosine deaminase (CD) gene/5-fluorocytosine (5-FC) system is superior to the herpes simplex virus thymidine kinase (HSV-TK) gene/ganciclovir (GCV) system, we examined here which suicide gene system was more promising in vivo for the treatment of hepatocellular carcinoma (HCC).

Methods: BNL1ME A.7R.1 murine HCC cells were retrovirally transduced with the HSV-TK or CD gene, and bystander effects caused by the appropriate prodrug treatment were examined not only in vitro but also in vivo.

Results: The CD/5-FC system was superior to the HSV-TK/GCV system in HCC cell elimination in vitro. The bystander effect of the HSV-TK/GCV was shown to be substantially dependent on cell-to-cell contact, whereas that of the CD/5-FC was not. However, antitumor effects on HCC and tumor immunity to parental HCC induced by the HSV-TK/GCV system were not inferior and even superior to those induced by the CD/5-FC system. Bystander effects induced by the suicide gene/prodrug systems in immunocompetent syngeneic mice were much more profound than those induced in vitro. However, significant bystander effects were not observed in athymic nude mice.

Conclusions: These results suggest that both HSV-TK/GCV and CD/5-FC systems are useful for the treatment of HCC. The results also suggest that T-cell-mediated immune responses elicited by the suicide gene/prodrug systems play a substantial role in antitumor effects in vivo.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antifungal Agents / therapeutic use
  • Antiviral Agents / therapeutic use
  • Carcinoma, Hepatocellular / therapy*
  • Cytosine Deaminase
  • Escherichia coli / enzymology
  • Escherichia coli / genetics*
  • Female
  • Flucytosine / therapeutic use
  • Ganciclovir / therapeutic use
  • Gene Transfer Techniques
  • Genetic Therapy*
  • Genetic Vectors
  • Liver Neoplasms / therapy*
  • Mice
  • Mice, Inbred BALB C
  • Mice, Nude
  • Nucleoside Deaminases / genetics*
  • Prodrugs / therapeutic use
  • Simplexvirus / enzymology
  • Simplexvirus / genetics*
  • Statistics, Nonparametric
  • Thymidine Kinase / genetics*
  • Tumor Cells, Cultured

Substances

  • Antifungal Agents
  • Antiviral Agents
  • Prodrugs
  • Flucytosine
  • Thymidine Kinase
  • Nucleoside Deaminases
  • Cytosine Deaminase
  • Ganciclovir